TrialCancer immunology, immunotherapy : CII2017

Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.

Maria Winqvist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.